Novo Nordisk A/S (NYSE:NVO) Shares Bought by Souders Financial Advisors

Souders Financial Advisors raised its holdings in Novo Nordisk A/S (NYSE:NVO) by 0.6% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 39,696 shares of the company’s stock after purchasing an additional 230 shares during the period. Souders Financial Advisors’ holdings in Novo Nordisk A/S were worth $5,666,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in NVO. First PREMIER Bank bought a new position in shares of Novo Nordisk A/S in the first quarter worth $25,000. 1620 Investment Advisors Inc. purchased a new stake in Novo Nordisk A/S in the 2nd quarter worth about $25,000. Dixon Mitchell Investment Counsel Inc. purchased a new stake in shares of Novo Nordisk A/S during the 1st quarter worth about $26,000. Orion Capital Management LLC purchased a new stake in shares of Novo Nordisk A/S during the 1st quarter worth about $26,000. Finally, Gilliland Jeter Wealth Management LLC raised its stake in shares of Novo Nordisk A/S by 200.0% during the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after purchasing an additional 120 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $119.05 on Tuesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 0.94 and a quick ratio of 0.75. The business has a 50-day simple moving average of $131.69 and a 200 day simple moving average of $132.87. The firm has a market capitalization of $534.24 billion, a price-to-earnings ratio of 41.05, a PEG ratio of 1.35 and a beta of 0.42. Novo Nordisk A/S has a one year low of $86.96 and a one year high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, August 7th. The company reported $0.65 EPS for the quarter, missing the consensus estimate of $0.71 by ($0.06). Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. The firm had revenue of $9.82 billion during the quarter, compared to analysts’ expectations of $9.91 billion. On average, research analysts anticipate that Novo Nordisk A/S will post 3.11 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 16th were paid a $0.5126 dividend. The ex-dividend date was Friday, August 16th. This represents a yield of 0.7%. Novo Nordisk A/S’s dividend payout ratio is presently 24.83%.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on NVO. Argus raised their target price on Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a report on Monday, June 10th. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Monday, September 16th. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. Finally, BMO Capital Markets decreased their target price on Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating for the company in a research note on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $145.17.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.